| Year |
Citation |
Score |
| 2023 |
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, ... ... Mouillac B, et al. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. British Journal of Pharmacology. S23-S144. PMID 38123151 DOI: 10.1111/bph.16177 |
0.35 |
|
| 2023 |
Bous J, Fouillen A, Orcel H, Granier S, Bron P, Mouillac B. Structures of the arginine-vasopressin and oxytocin receptor signaling complexes. Vitamins and Hormones. 123: 67-107. PMID 37718002 DOI: 10.1016/bs.vh.2022.12.003 |
0.487 |
|
| 2023 |
Fouillen A, Bous J, Granier S, Mouillac B, Sounier R. Bringing GPCR Structural Biology to Medical Applications: Insights from Both V2 Vasopressin and Mu-Opioid Receptors. Membranes. 13. PMID 37367810 DOI: 10.3390/membranes13060606 |
0.425 |
|
| 2022 |
Bous J, Fouillen A, Orcel H, Trapani S, Cong X, Fontanel S, Saint-Paul J, Lai-Kee-Him J, Urbach S, Sibille N, Sounier R, Granier S, Mouillac B, Bron P. Structure of the vasopressin hormone-V2 receptor-β-arrestin1 ternary complex. Science Advances. 8: eabo7761. PMID 36054364 DOI: 10.1126/sciadv.abo7761 |
0.397 |
|
| 2022 |
Szalai L, Sziráki A, Erdélyi LS, Kovács KB, Tóth M, Tóth AD, Turu G, Bonnet D, Mouillac B, Hunyady L, Balla A. Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones. Frontiers in Pharmacology. 13: 811836. PMID 35153784 DOI: 10.3389/fphar.2022.811836 |
0.429 |
|
| 2022 |
Droctové L, Ciolek J, Mendre C, Chorfa A, Huerta P, Carvalho C, Gouin C, Lancien M, Stanajic-Petrovic G, Braco L, Blanchet G, Upert G, De Pauw E, Barbe P, Keck M, ... ... Mouillac B, et al. A new Kunitz-type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor. British Journal of Pharmacology. PMID 35122240 DOI: 10.1111/bph.15814 |
0.708 |
|
| 2021 |
Alexander SP, Christopoulos A, Davenport AP, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Abbracchio MP, Alexander W, ... ... Mouillac B, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology. 178: S27-S156. PMID 34529832 DOI: 10.1111/bph.15538 |
0.344 |
|
| 2021 |
Bous J, Orcel H, Floquet N, Leyrat C, Lai-Kee-Him J, Gaibelet G, Ancelin A, Saint-Paul J, Trapani S, Louet M, Sounier R, Déméné H, Granier S, Bron P, Mouillac B. Cryo-electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex. Science Advances. 7. PMID 34020960 DOI: 10.1126/sciadv.abg5628 |
0.392 |
|
| 2021 |
Lemel L, Nieścierowicz K, García-Fernández MD, Darré L, Durroux T, Busnelli M, Pezet M, Rebeille F, Jouhet J, Mouillac B, Domene C, Chini B, Cherezov V, Moreau CJ. The ligand-bound state of a G protein-coupled receptor stabilizes the interaction of functional cholesterol molecules. Journal of Lipid Research. 100059. PMID 33647276 DOI: 10.1016/j.jlr.2021.100059 |
0.392 |
|
| 2020 |
Droctové L, Lancien M, Tran VL, Susset M, Jego B, Theodoro F, Kessler P, Mourier G, Robin P, Diarra SS, Palea S, Flahault A, Chorfa A, Corbani M, Llorens-Cortes C, ... Mouillac B, et al. A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Theranostics. 10: 11580-11594. PMID 33052234 DOI: 10.7150/thno.47485 |
0.7 |
|
| 2019 |
Mendre C, Mouillac B. Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics. Advances in Protein Chemistry and Structural Biology. 118: 249-272. PMID 31928727 DOI: 10.1016/Bs.Apcsb.2019.07.002 |
0.819 |
|
| 2019 |
Heuninck J, Hounsou C, Dupuis E, Trinquet E, Mouillac B, Pin JP, Bonnet D, Durroux T. Time-Resolved FRET-Based Assays to Characterize G Protein-Coupled Receptor Hetero-oligomer Pharmacology. Methods in Molecular Biology (Clifton, N.J.). 1947: 151-168. PMID 30969415 DOI: 10.1007/978-1-4939-9121-1_8 |
0.511 |
|
| 2019 |
Bichet D, Bouvier M, Chini B, Gimpl G, Guillon G, Kimura T, Knepper M, Lolait S, Manning M, Mouillac B, O'Carroll A, Serradeil-Le Gal C, Soloff M, Verbalis JG, Wheatley M, et al. Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Iuphar/Bps Guide to Pharmacology Cite. 2019. DOI: 10.2218/gtopdb/f66/2019.4 |
0.539 |
|
| 2018 |
Frantz MC, Pellissier L, Pflimlin E, Loison S, Gandia J, Marsol C, Durroux T, Mouillac B, Becker J, Le Merrer J, Valencia C, Villa P, Bonnet D, Hibert M. LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. Journal of Medicinal Chemistry. PMID 30199637 DOI: 10.1021/Acs.Jmedchem.8B00697 |
0.518 |
|
| 2018 |
Droctové L, Ciolek J, Lancien M, Stura EA, Vera L, Floquet N, Witzgall R, Mouillac B, Mendre C, Mourier G, Servent D, Gilles N. Crystal structure and functional domains of the Mambaquaretin-1, a vasopressin type 2 receptor peptide inhibitor for kidney cysts treatment Toxicon. 149: 91-92. DOI: 10.1016/J.Toxicon.2017.12.021 |
0.716 |
|
| 2017 |
Perkovska S, Méjean C, Ayoub MA, Li J, Hemery F, Corbani M, Laguette N, Ventura MA, Orcel H, Durroux T, Mouillac B, Mendre C. V1b vasopressin receptor trafficking and signaling : role of arrestins, G proteins and Src kinase. Traffic (Copenhagen, Denmark). PMID 29044966 DOI: 10.1111/Tra.12535 |
0.81 |
|
| 2017 |
Mouillac B, Mendre C. Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors. Handbook of Experimental Pharmacology. PMID 28939971 DOI: 10.1007/164_2017_50 |
0.814 |
|
| 2017 |
Recio R, Vengut-Climent E, Mouillac B, Orcel H, López-Lázaro M, Calderón-Montaño JM, Álvarez E, Khiar N, Fernández I. Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification. European Journal of Medicinal Chemistry. 138: 644-660. PMID 28710964 DOI: 10.1016/J.Ejmech.2017.06.056 |
0.428 |
|
| 2017 |
Ciolek J, Reinfrank H, Quinton L, Viengchareun S, Stura EA, Vera L, Sigismeau S, Mouillac B, Orcel H, Peigneur S, Tytgat J, Droctové L, Beau F, Nevoux J, Lombès M, et al. Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 28630289 DOI: 10.1073/Pnas.1620454114 |
0.747 |
|
| 2016 |
Rossato M, Miralles G, M'Kadmi C, Maingot M, Amblard M, Mouillac B, Gagne D, Martinez J, Subra G, Enjalbal C, Cantel S. Quantitative MALDI-MS Binding Assays: An Alternative to Radiolabeling. Chemmedchem. 11: 2582-2587. PMID 27922213 DOI: 10.1002/Cmdc.201600447 |
0.424 |
|
| 2016 |
Ciolek J, Reinfrank H, Servent D, Mourier G, Mouillac B, Quinton L, Mendre C, Witzgall R, Gilles N. Activity of Mambaquaretin toxin on kidney disease via its interaction with vasopressin V2 receptor Toxicon. 116: 76. DOI: 10.1016/J.Toxicon.2016.01.016 |
0.752 |
|
| 2015 |
Faklaris O, Cottet M, Falco A, Villier B, Laget M, Zwier JM, Trinquet E, Mouillac B, Pin JP, Durroux T. Multicolor time-resolved Förster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 29: 2235-46. PMID 25690655 DOI: 10.1096/Fj.14-260059 |
0.388 |
|
| 2015 |
Damian M, Mary S, Maingot M, M'Kadmi C, Gagne D, Leyris JP, Denoyelle S, Gaibelet G, Gavara L, Garcia de Souza Costa M, Perahia D, Trinquet E, Mouillac B, Galandrin S, Galès C, et al. Ghrelin receptor conformational dynamics regulate the transition from a preassembled to an active receptor:Gq complex. Proceedings of the National Academy of Sciences of the United States of America. 112: 1601-6. PMID 25605885 DOI: 10.1073/Pnas.1414618112 |
0.852 |
|
| 2014 |
Mary S, Damian M, Rahmeh R, Mouillac B, Marie J, Granier S, Banères JL. Amphipols in G protein-coupled receptor pharmacology: what are they good for? The Journal of Membrane Biology. 247: 853-60. PMID 24801284 DOI: 10.1007/S00232-014-9665-9 |
0.844 |
|
| 2014 |
Karpenko IA, Kreder R, Valencia C, Villa P, Mendre C, Mouillac B, Mély Y, Hibert M, Bonnet D, Klymchenko AS. Red fluorescent turn-on ligands for imaging and quantifying G protein-coupled receptors in living cells. Chembiochem : a European Journal of Chemical Biology. 15: 359-63. PMID 24449564 DOI: 10.1002/Cbic.201300738 |
0.792 |
|
| 2014 |
Mouillac B, Mendre C. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies. Pharmacological Research. 83: 74-8. PMID 24239889 DOI: 10.1016/J.Phrs.2013.10.007 |
0.795 |
|
| 2013 |
Mary S, Fehrentz JA, Damian M, Gaibelet G, Orcel H, Verdié P, Mouillac B, Martinez J, Marie J, Banères JL. Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: a study with a purified heterodimer assembled into lipid discs. The Journal of Biological Chemistry. 288: 24656-65. PMID 23839942 DOI: 10.1074/Jbc.M113.453423 |
0.579 |
|
| 2013 |
Cottet M, Faklaris O, Falco A, Trinquet E, Pin JP, Mouillac B, Durroux T. Fluorescent ligands to investigate GPCR binding properties and oligomerization. Biochemical Society Transactions. 41: 148-53. PMID 23356275 DOI: 10.1042/Bst20120237 |
0.468 |
|
| 2012 |
Banères JL, Mouillac B. [Handling G-protein-coupled receptors: expression, purification and in vitro stabilization]. Medecine Sciences : M/S. 28: 837-44. PMID 23067414 DOI: 10.1051/Medsci/20122810011 |
0.494 |
|
| 2012 |
El Moustaine D, Granier S, Doumazane E, Scholler P, Rahmeh R, Bron P, Mouillac B, Banères JL, Rondard P, Pin JP. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling. Proceedings of the National Academy of Sciences of the United States of America. 109: 16342-7. PMID 22988116 DOI: 10.1073/Pnas.1205838109 |
0.817 |
|
| 2012 |
Loison S, Cottet M, Orcel H, Adihou H, Rahmeh R, Lamarque L, Trinquet E, Kellenberger E, Hibert M, Durroux T, Mouillac B, Bonnet D. Selective fluorescent nonpeptidic antagonists for vasopressin V2 GPCR: Application to ligand screening and oligomerization assays. Journal of Medicinal Chemistry. 55: 8588-8602. PMID 22984902 DOI: 10.1021/Jm3006146 |
0.794 |
|
| 2012 |
Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T, Sharma KS, Durand G, Pucci B, Trinquet E, Zwier JM, Deupi X, Bron P, Banères JL, Mouillac B, et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proceedings of the National Academy of Sciences of the United States of America. 109: 6733-8. PMID 22493271 DOI: 10.1073/Pnas.1201093109 |
0.833 |
|
| 2012 |
Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G. Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics. Journal of Neuroendocrinology. 24: 609-28. PMID 22375852 DOI: 10.1111/J.1365-2826.2012.02303.X |
0.451 |
|
| 2011 |
Cottet M, Albizu L, Comps-Agrar L, Trinquet E, Pin JP, Mouillac B, Durroux T. Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization. Methods in Molecular Biology (Clifton, N.J.). 746: 373-87. PMID 21607869 DOI: 10.1007/978-1-61779-126-0_21 |
0.523 |
|
| 2011 |
Bellot G, Pascal R, Mendre C, Urbach S, Mouillac B, Déméné H. Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor Protein Expression and Purification. 78: 131-138. PMID 21575724 DOI: 10.1016/J.Pep.2011.04.020 |
0.778 |
|
| 2011 |
Banères JL, Popot JL, Mouillac B. New advances in production and functional folding of G-protein-coupled receptors. Trends in Biotechnology. 29: 314-22. PMID 21497924 DOI: 10.1016/J.Tibtech.2011.03.002 |
0.469 |
|
| 2010 |
Albizu L, Cottet M, Kralikova M, Stoev S, Seyer R, Brabet I, Roux T, Bazin H, Bourrier E, Lamarque L, Breton C, Rives ML, Newman A, Javitch J, Trinquet E, ... ... Mouillac B, et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nature Chemical Biology. 6: 587-94. PMID 20622858 DOI: 10.1038/Nchembio.396 |
0.56 |
|
| 2010 |
Mendre C, Mouillac B. [Pharmacological chaperones: a potential therapeutic treatment for conformational diseases]. Medecine Sciences : M/S. 26: 627-35. PMID 20619166 DOI: 10.1051/Medsci/2010266-7627 |
0.712 |
|
| 2010 |
Frantz MC, Rodrigo J, Boudier L, Durroux T, Mouillac B, Hibert M. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist. Journal of Medicinal Chemistry. 53: 1546-62. PMID 20104850 DOI: 10.1021/Jm901084F |
0.528 |
|
| 2010 |
Mouillac B, Banères JL. Mammalian membrane receptors expression as inclusion bodies in Escherichia coli. Methods in Molecular Biology (Clifton, N.J.). 601: 39-48. PMID 20099138 DOI: 10.1007/978-1-60761-344-2_3 |
0.516 |
|
| 2010 |
Arcemisbéhère L, Sen T, Boudier L, Balestre MN, Gaibelet G, Detouillon E, Orcel H, Mendre C, Rahmeh R, Granier S, Vivès C, Fieschi F, Damian M, Durroux T, Banères JL, ... Mouillac B, et al. Leukotriene BLT2 receptor monomers activate the Gi2 GTP-binding protein more efficiently than dimers Journal of Biological Chemistry. 285: 6337-6347. PMID 20026606 DOI: 10.1074/Jbc.M109.083477 |
0.806 |
|
| 2010 |
Cottet M, Albizu L, Perkovska S, Jean-Alphonse F, Rahmeh R, Orcel H, Méjean C, Granier S, Mendre C, Mouillac B, Durroux T. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes. Current Opinion in Pharmacology. 10: 59-66. PMID 19896898 DOI: 10.1016/J.Coph.2009.10.003 |
0.813 |
|
| 2010 |
Tenenbaum J, Ayoub M, Perkovska S, Adra-Delenne A, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D. CL110 - Le syndrome d’antidiurèse inappropriée néphrogénique (NSIAD) : une pathologie récente et encore méconnue Archives De PéDiatrie. 17: 30. DOI: 10.1016/S0929-693X(10)70326-2 |
0.734 |
|
| 2009 |
Tenenbaum J, Ayoub MA, Perkovska S, Adra-Delenne AL, Mendre C, Ranchin B, Bricca G, Geelen G, Mouillac B, Durroux T, Morin D. The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation. Plos One. 4: e8383. PMID 20027297 DOI: 10.1371/Journal.Pone.0008383 |
0.833 |
|
| 2009 |
Jean-Alphonse F, Perkovska S, Frantz MC, Durroux T, Méjean C, Morin D, Loison S, Bonnet D, Hibert M, Mouillac B, Mendre C. Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus. Journal of the American Society of Nephrology : Jasn. 20: 2190-203. PMID 19729439 DOI: 10.1681/Asn.2008121289 |
0.806 |
|
| 2009 |
Bellot G, Granier S, Bourguet W, Seyer R, Rahmeh R, Mouillac B, Pascal R, Mendre C, Déméné H. Structure of the Third Intracellular Loop of the Vasopressin V2 Receptor and Conformational Changes upon Binding to gC1qR Journal of Molecular Biology. 388: 491-507. PMID 19285506 DOI: 10.1016/J.Jmb.2009.02.065 |
0.832 |
|
| 2009 |
Orcel H, Albizu L, Perkovska S, Durroux T, Mendre C, Ansanay H, Mouillac B, Rabié A. Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. Molecular Pharmacology. 75: 637-47. PMID 19047484 DOI: 10.1124/Mol.108.049031 |
0.814 |
|
| 2008 |
Mouillac B, Manning M, Durroux T. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies. Mini Reviews in Medicinal Chemistry. 8: 996-1005. PMID 18782052 DOI: 10.2174/138955708785740607 |
0.582 |
|
| 2008 |
Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Progress in Brain Research. 170: 473-512. PMID 18655903 DOI: 10.1016/S0079-6123(08)00437-8 |
0.43 |
|
| 2008 |
Bonnet D, Riché S, Loison S, Dagher R, Frantz MC, Boudier L, Rahmeh R, Mouillac B, Haiech J, Hibert M. Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin receptor ligand. Chemistry (Weinheim An Der Bergstrasse, Germany). 14: 6247-54. PMID 18512866 DOI: 10.1002/Chem.200800273 |
0.768 |
|
| 2008 |
Granier S, Jean-Alphonse F, Bacqueville D, Monteil A, Pascal R, Poncet J, Guillon G, Boudier L, Arcemisbéhère L, Mouillac B, Bellot G, Déméné H, Mendre C. The multifunctional protein GC1q-R interacts specifically with the i3 loop arginine cluster of the vasopressin V2 receptor Regulatory Peptides. 148: 76-87. PMID 18358546 DOI: 10.1016/J.Regpep.2008.01.007 |
0.779 |
|
| 2007 |
Albizu L, Teppaz G, Seyer R, Bazin H, Ansanay H, Manning M, Mouillac B, Durroux T. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. Journal of Medicinal Chemistry. 50: 4976-85. PMID 17850055 DOI: 10.1021/Jm061404Q |
0.809 |
|
| 2006 |
Albizu L, Balestre MN, Breton C, Pin JP, Manning M, Mouillac B, Barberis C, Durroux T. Probing the existence of G protein-coupled receptor dimers by positive and negative ligand-dependent cooperative binding. Molecular Pharmacology. 70: 1783-91. PMID 16926282 DOI: 10.1124/Mol.106.025684 |
0.488 |
|
| 2006 |
Alves ID, Delaroche D, Mouillac B, Salamon Z, Tollin G, Hruby VJ, Lavielle S, Sagan S. The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy. Biochemistry. 45: 5309-18. PMID 16618119 DOI: 10.1021/Bi052586D |
0.412 |
|
| 2005 |
Manning M, Cheng LL, Stoev S, Wo NC, Chan WY, Szeto HH, Durroux T, Mouillac B, Barberis C. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban. Journal of Peptide Science : An Official Publication of the European Peptide Society. 11: 593-608. PMID 15880385 DOI: 10.1002/Psc.667 |
0.335 |
|
| 2005 |
Ponthieux S, Cabot J, Mouillac B, Seyer R, Barberis C, Carnazzi E. Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties. Journal of Medicinal Chemistry. 48: 3379-88. PMID 15857144 DOI: 10.1021/Jm040871+ |
0.396 |
|
| 2005 |
Duroux-Richard I, Vassault P, Subra G, Guichou JF, Richard E, Mouillac B, Barberis C, Marie J, Bonnafous JC. Crosslinking photosensitized by a ruthenium chelate as a tool for labeling and topographical studies of G-protein-coupled receptors. Chemistry & Biology. 12: 15-24. PMID 15664511 DOI: 10.1016/J.Chembiol.2004.10.008 |
0.581 |
|
| 2005 |
Levoye A, Mouillac B, Rivière G, Vieau D, Salzet M, Breton C. Cloning, expression and pharmacological characterization of a vasopressin-related receptor in an annelid, the leech Theromyzon tessulatum. The Journal of Endocrinology. 184: 277-89. PMID 15642804 DOI: 10.1677/JOE.1.05833 |
0.477 |
|
| 2003 |
Tahtaoui C, Balestre MN, Klotz P, Rognan D, Barberis C, Mouillac B, Hibert M. Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors. The Journal of Biological Chemistry. 278: 40010-9. PMID 12869559 DOI: 10.1074/Jbc.M301128200 |
0.531 |
|
| 2003 |
Terrillon S, Durroux T, Mouillac B, Breit A, Ayoub MA, Taulan M, Jockers R, Barberis C, Bouvier M. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Molecular Endocrinology (Baltimore, Md.). 17: 677-91. PMID 12554793 DOI: 10.1210/Me.2002-0222 |
0.851 |
|
| 2002 |
Mouillac B, Sen T, Durroux T, Gaibelet G, Barberis C. Expression of human vasopressin and oxytocin receptors in Escherichia coli. Progress in Brain Research. 139: 163-77. PMID 12436934 DOI: 10.1016/S0079-6123(02)39015-0 |
0.474 |
|
| 2002 |
Terrillon S, Cheng LL, Stoev S, Mouillac B, Barberis C, Manning M, Durroux T. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors. Journal of Medicinal Chemistry. 45: 2579-88. PMID 12036367 DOI: 10.1021/Jm010526+ |
0.807 |
|
| 2001 |
Carnazzi E, Aumelas A, Mouillac B, Breton C, Guillou L, Barberis C, Seyer R. Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist. Journal of Medicinal Chemistry. 44: 3022-30. PMID 11520211 DOI: 10.1021/Jm010125U |
0.39 |
|
| 2001 |
Breton C, Chellil H, Kabbaj-Benmansour M, Carnazzi E, Seyer R, Phalipou S, Morin D, Durroux T, Zingg H, Barberis C, Mouillac B. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor. The Journal of Biological Chemistry. 276: 26931-41. PMID 11337500 DOI: 10.1074/Jbc.M102073200 |
0.479 |
|
| 2000 |
Cotte N, Balestre MN, Aumelas A, Mahé E, Phalipou S, Morin D, Hibert M, Manning M, Durroux T, Barberis C, Mouillac B. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding. European Journal of Biochemistry. 267: 4253-63. PMID 10866830 DOI: 10.1046/J.1432-1033.2000.01472.X |
0.505 |
|
| 1999 |
Phalipou S, Seyer R, Cotte N, Breton C, Barberis C, Hibert M, Mouillac B. Docking of linear peptide antagonists into the human V(1a) vasopressin receptor. Identification of binding domains by photoaffinity labeling. The Journal of Biological Chemistry. 274: 23316-27. PMID 10438508 DOI: 10.1074/Jbc.274.33.23316 |
0.499 |
|
| 1999 |
Hibert M, Hoflack J, Trumpp-Kallmeyer S, Mouillac B, Chini B, Mahé E, Cotte N, Jard S, Manning M, Barberis C. Functional architecture of vasopressin/oxytocin receptors. Journal of Receptor and Signal Transduction Research. 19: 589-96. PMID 10071787 DOI: 10.3109/10799899909036674 |
0.464 |
|
| 1999 |
Mouillac B, Phalipou S, Cotte N, Balestre MN, Hibert M, Manning M, Barberis C. Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors. Advances in Experimental Medicine and Biology. 449: 359-61. PMID 10026825 DOI: 10.1007/978-1-4615-4871-3_45 |
0.568 |
|
| 1999 |
Zingg HH, Grazzini E, Breton C, Larcher A, Rozen F, Russo C, Guillon G, Mouillac B. Genomic and non-genomic mechanisms of oxytocin receptor regulation. Advances in Experimental Medicine and Biology. 449: 287-95. PMID 10026816 DOI: 10.1007/978-1-4615-4871-3_36 |
0.428 |
|
| 1999 |
Morin D, Cotte N, Balestre MN, Mouillac B, Manning M, Breton C, Barberis C. The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities. Febs Letters. 441: 470-5. PMID 9891993 DOI: 10.1016/S0014-5793(98)01585-3 |
0.521 |
|
| 1999 |
Barberis C, Morin D, Durroux T, Mouillac B, Guillon G, Seyer R, Hibert M, Tribollet E, Manning M. Molecular pharmacology of AVP and OT receptors and therapeutic potential Drug News & Perspectives. 12: 279. DOI: 10.1358/Dnp.1999.12.5.863621 |
0.488 |
|
| 1998 |
Cotte N, Balestre MN, Phalipou S, Hibert M, Manning M, Barberis C, Mouillac B. Identification of residues responsible for the selective binding of peptide antagonists and agonists in the V2 vasopressin receptor. The Journal of Biological Chemistry. 273: 29462-8. PMID 9792651 DOI: 10.1074/jbc.273.45.29462 |
0.407 |
|
| 1998 |
Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature. 392: 509-12. PMID 9548257 DOI: 10.1038/33176 |
0.502 |
|
| 1998 |
Barberis C, Mouillac B, Durroux T. Structural bases of vasopressin/oxytocin receptor function. The Journal of Endocrinology. 156: 223-9. PMID 9518866 DOI: 10.1677/JOE.0.1560223 |
0.37 |
|
| 1997 |
Phalipou S, Cotte N, Carnazzi E, Seyer R, Mahe E, Jard S, Barberis C, Mouillac B. Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. The Journal of Biological Chemistry. 272: 26536-44. PMID 9334232 DOI: 10.1074/Jbc.272.42.26536 |
0.554 |
|
| 1997 |
Carnazzi E, Aumelas A, Phalipou S, Mouillac B, Guillon G, Barberis C, Seyer R. Efficient photoaffinity labeling of the rat V1a vasopressin receptor using a linear azidopeptidic antagonist. European Journal of Biochemistry. 247: 906-13. PMID 9288914 DOI: 10.1111/J.1432-1033.1997.00906.X |
0.544 |
|
| 1997 |
Ala Y, Morin D, Mahé E, Cotte N, Mouillac B, Jard S, Barberis C, Tribollet E, Dreifuss JJ, Sawyer WH, Wo NC, Chan WY, Kolodziejczyk AS, Cheng LL, Manning M. Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors. European Journal of Pharmacology. 331: 285-93. PMID 9274991 DOI: 10.1016/S0014-2999(97)01021-2 |
0.479 |
|
| 1997 |
Chini B, Mouillac B, Ala Y, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C. Identification of a single residue responsible for agonist selectivity in the oxytocin-vasopressin receptors. Annals of the New York Academy of Sciences. 812: 218-21. PMID 9186749 DOI: 10.1111/J.1749-6632.1997.Tb48181.X |
0.485 |
|
| 1997 |
Rousseau G, Guilbault N, Da Silva A, Mouillac B, Chidiac P, Bouvier M. Influence of receptor density on the patterns of beta2-adrenocepter desensitization. European Journal of Pharmacology. 326: 75-84. PMID 9178658 DOI: 10.1016/S0014-2999(97)00138-6 |
0.793 |
|
| 1996 |
Chini B, Mouillac B, Balestre MN, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Andriolo M, Pupier S, Jard S, Barberis C. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin. Febs Letters. 397: 201-6. PMID 8955347 DOI: 10.1016/S0014-5793(96)01135-0 |
0.547 |
|
| 1996 |
Moffett S, Adam L, Bonin H, Loisel TP, Bouvier M, Mouillac B. Palmitoylated cysteine 341 modulates phosphorylation of the beta2-adrenergic receptor by the cAMP-dependent protein kinase. The Journal of Biological Chemistry. 271: 21490-7. PMID 8702933 DOI: 10.1074/Jbc.271.35.21490 |
0.833 |
|
| 1996 |
Hibert M, Hoflack J, Trumpp-Kallmeyer S, Paquet JL, Leppik R, Mouillac B, Chini B, Barberis C, Jard S. Three-dimensional structure of G protein-coupled receptors: from speculations to facts Pharmacochemistry Library. 24: 205-214. DOI: 10.1016/S0165-7208(96)80017-1 |
0.565 |
|
| 1995 |
Bouvier M, Moffett S, Loisel TP, Mouillac B, Hebert T, Chidiac P. Palmitoylation of G-protein-coupled receptors: a dynamic modification with functional consequences. Biochemical Society Transactions. 23: 116-20. PMID 7758677 DOI: 10.1042/Bst0230116 |
0.799 |
|
| 1995 |
Bouvier M, Chidiac P, Hebert TE, Loisel TP, Moffett S, Mouillac B. Dynamic palmitoylation of G-protein-coupled receptors in eukaryotic cells. Methods in Enzymology. 250: 300-14. PMID 7651160 DOI: 10.1016/0076-6879(95)50080-4 |
0.842 |
|
| 1995 |
Mouillac B, Chini B, Balestre MN, Elands J, Trumpp-Kallmeyer S, Hoflack J, Hibert M, Jard S, Barberis C. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. The Journal of Biological Chemistry. 270: 25771-7. PMID 7592759 DOI: 10.1074/Jbc.270.43.25771 |
0.511 |
|
| 1995 |
Trumpp-Kallmeyer S, Chini B, Mouillac B, Barberis C, Hoflack J, Hibert M. Towards understanding the role of the first extracellular loop for the binding of peptide hormones to G-protein coupled receptors. Pharmaceutica Acta Helvetiae. 70: 255-62. PMID 7480069 DOI: 10.1016/0031-6865(95)00029-9 |
0.556 |
|
| 1995 |
Bouvier M, Nantel F, Valiquette M, Moffett S, Mouillac B. Le récepteur β2-adrénergique. Un modèle d'étude des mécanismes moléculaires de la désensibilisation MéDecine/Sciences. 11: 819. DOI: 10.4267/10608/2293 |
0.744 |
|
| 1995 |
Trumpp-Kallmeyer S, Hoflack J, Hibert M, Chini B, Mouillac B, Barberis C. Investigation of receptor-ligand interactions of the Oxytocin/Vasopressin receptor family by molecular modeling and site directed mutagenesis studies Pharmacological Research. 31: 302. DOI: 10.1016/1043-6618(95)87468-2 |
0.497 |
|
| 1995 |
Chini B, Mouillac B, Ala Y, Balestre M, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S, Barberis C. Identification of a single residue responsible for agonist selectivity in the oxytocin-vasopressin receptors Pharmacological Research. 31: 190. DOI: 10.1016/1043-6618(95)87020-2 |
0.485 |
|
| 1995 |
Chini B, Mouillac B, Ala Y, Balestre M, Trumpp-Kallmeyer S, Hoflack J, Elands J, Hibert M, Manning M, Jard S. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor. The Embo Journal. 14: 2176-2182. DOI: 10.1002/J.1460-2075.1995.Tb07211.X |
0.568 |
|
| 1994 |
Ng GY, Mouillac B, George SR, Caron M, Dennis M, Bouvier M, O'Dowd BF. Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor. European Journal of Pharmacology. 267: 7-19. PMID 7515822 DOI: 10.1016/0922-4106(94)90219-4 |
0.567 |
|
| 1987 |
Guillon G, Balestre MN, Mouillac B, Berrada R, Kirk CJ. Mechanisms of phospholipase C activation: a comparison with the adenylate cyclase system Biochimie. 69: 351-363. PMID 3115315 DOI: 10.1016/0300-9084(87)90026-5 |
0.444 |
|
| 1986 |
Guillon G, Balestre MN, Mouillac B, Devilliers G. Activation of membrane phospholipase C by vasopressin. A requirement for guanyl nucleotides. Febs Letters. 196: 155-9. PMID 3943628 DOI: 10.1016/0014-5793(86)80232-0 |
0.312 |
|
| 1986 |
Guillon G, Mouillac B, Balestre MN. Activation of polyphosphoinositide phospholipase C by fluoride in WRK1 cell membranes. Febs Letters. 204: 183-8. PMID 3015678 DOI: 10.1016/0014-5793(86)80808-0 |
0.373 |
|
| Show low-probability matches. |